A Study of ILB2109 in Patients With Advanced Solid Malignancies
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and
preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced
or metastatic solid malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Innolake Biopharm
Collaborators:
Shandong Cancer Hospital and Institute Shanghai East Hospital